Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Liposomal Doxorubicin and Docetaxel in Breast Cancer
NCT03221881Completed
- Sponsor
- The Fourth Hospital of Hebei Medical University
- Start
- Jan 2015
- Primary completion
- Apr 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label, single-arm trial of doxorubicin in breast cancer, sponsored by The Fourth Hospital of Hebei Medical University. Primary endpoint: Pathological Complete Response rate at 12 months. Started Jan 2015; status: completed.
02
Drugs
doxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03221881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03221881.